Takeda touts interim PhIII data of enzyme replacement therapy for rare blood disease

Takeda says in an interim Phase III analysis that its enzyme replacement therapy reduced instances of low blood platelet count for patients with a rare blood clot disorder known as congenital thrombotic thrombocytopenic purpura (cTTP) compared to standard of care plasma-based therapies.